Genetic factors are reviewed for their contribution to aspirin resistance, defined as the failure of aspirin to inhibit platelet aggregation or thromboxane A2 synthesis.
Do genetic factors contribute to aspirin resistance in patients receiving aspirin for cardiovascular prophylaxis?
This review summarizes the evidence regarding the genetic contribution to aspirin resistance in patients receiving cardiovascular prophylaxis.
Aspirin is widely used for the prophylaxis of cardiovascular events in patients with cardiovascular risk factors or established atherosclerotic disease. However, despite aspirin treatment, a substantial number of patients experience recurrent events. Such 'aspirin resistance' is generally defined as failure of aspirin to produce an expected biological response, for example inhibition of platelet aggregation or of thromboxane A2 synthesis. Whilst its aetiology is multifactorial, genetic factors are also likely to play their part. Here we review the evidence for and against such a genetic contribution, as well as the data suggesting the involvement of specific genes.
Goodman et al. (Wed,) conducted a review in Aspirin resistance in cardiovascular disease. Aspirin was evaluated. Genetic factors are reviewed for their contribution to aspirin resistance, defined as the failure of aspirin to inhibit platelet aggregation or thromboxane A2 synthesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: